Ruxolitinib Cream + Vehicle Cream
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hidradenitis Suppurativa
Conditions
Hidradenitis Suppurativa
Trial Timeline
Jun 12, 2025 → Jul 11, 2027
NCT ID
NCT06958211About Ruxolitinib Cream + Vehicle Cream
Ruxolitinib Cream + Vehicle Cream is a phase 3 stage product being developed by Incyte for Hidradenitis Suppurativa. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06958211. Target conditions include Hidradenitis Suppurativa.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06804811 | Phase 3 | Recruiting |
| NCT06959225 | Phase 3 | Recruiting |
| NCT06958211 | Phase 3 | Recruiting |
| NCT06548360 | Phase 3 | Recruiting |
| NCT06238817 | Phase 3 | Completed |
| NCT05764161 | Phase 3 | Completed |
| NCT05755438 | Phase 3 | Completed |
| NCT05635838 | Phase 2 | Completed |
| NCT05593432 | Phase 2 | Completed |
| NCT05593445 | Phase 2 | Completed |
| NCT04896385 | Phase 2 | Completed |
| NCT03745638 | Phase 3 | Completed |
| NCT03745651 | Phase 3 | Completed |
| NCT03099304 | Phase 2 | Completed |
Competing Products
20 competing products in Hidradenitis Suppurativa
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sonelokimab | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab + Placebo | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab + Placebo | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab (M1095) + Adalimumab | MoonLake Immunotherapeutics | Phase 2 | 47 |
| Eltrekibart + Placebo | Eli Lilly | Phase 2 | 52 |
| Placebo + LY3041658 | Eli Lilly | Phase 2 | 52 |
| Placebo + Adalimumab | AbbVie | Approved | 85 |
| Lutikizumab + Placebo | AbbVie | Phase 3 | 77 |
| Adalimumab | AbbVie | Pre-clinical | 23 |
| Upadacitinib + Placebo | AbbVie | Phase 3 | 77 |
| adalimumab + placebo | AbbVie | Phase 3 | 77 |
| Lutikizumab | AbbVie | Phase 2 | 52 |
| adalimumab | AbbVie | Phase 3 | 77 |
| Lutikizumab + Placebo | AbbVie | Phase 2 | 52 |
| Risankizumab + Placebo for risankizumab | AbbVie | Phase 2 | 52 |
| adalimumab | AbbVie | Phase 3 | 77 |
| adalimumab + placebo | AbbVie | Phase 3 | 77 |
| Upadacitinib + Placebo | AbbVie | Phase 2 | 52 |
| MEDI8968 + Saline | AstraZeneca | Phase 2 | 52 |